RCIXLabs Inc. welcomed Donna Rill as an advisor.

RCIXLabs is building the computational infrastructure for the next generation of T cell-based cell therapies - CAR-T, TIL, TCR-T, and in vivo approaches. Clinical trials in cell therapy fail not from lack of biology, but from lack of foresight. Our closed-loop mechanistic + ML platform simulates the entire therapy pipeline, from patient biology through manufacturing parameters, and clinical outcomes, giving cell therapy developers an unbiased tool to link clinical outcomes directly to manufacturing. By defining the target product profile and identifying the critical process parameters that drive critical quality attributes, the platform closes the loop between the lab and the clinic. The result: researchers can run thousands of virtual patients, stress-test protocols, optimize CMC processes, and surface non-responders, before a single patient is enrolled. The impact: 18–24 months faster development timelines, 40% reduction in manufacturing CMC costs, improved response rates, and stronger commercial viability. We work with: * Academic medical centers and cell therapy programs seeking computational trial design tools * Biotech and pharma companies developing T cell therapies who need faster, smarter iteration * Cell therapy platform developers who wants to stress test their platforms. * Seed and pre-seed investors backing AI-driven infrastructure for advanced therapeutics RCIXLabs is early-stage and actively building partnerships. If you're pushing the boundaries of cell therapy — in the clinic, in the lab, or in the boardroom — we want to hear from you. 📩 Reach us at info@rcixlabs.com

Founded 2026